Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients with Hemophilia A (NCT06941870)

This study will use MRI and Ultrasound techniques to help track the health of joints in patients with Haemophilia A taking Efanesoctocog Alfa Prophylaxis. The study will take place over the course of 1 year and will involve up to 5 outpatient visits (plus scans). The Efanesoctocog Alfa will be taken at home via IV (patients/guardians will be trained prior).

Trial phase

Phase 4

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Huyen Tran

Key inclusion data

Must have Haemophilia A. Must be at least 12 years old. Must have received some form of prophylaxis treatment for their Haemophilia in the past 12 months. Must not have any other associated clotting disorders. Must not be enrolled in any other clinical trials.